卖什么
Building programmable therapeutics for the immune system
商业模式拆解
触发点：什么让他们现在购买？
未核实Need for programmable, target-specific immune-system therapeutics for cancer, autoimmunity and infection.
经济账：省了什么，怎么收费？
Pre-commercial biotech: raised $7M+ seed from Felicis, Refactor and Y Combinator (2024); expected value from licensing/partnering or own drug development.
渠道：怎么接触到客户？
No commercial product; founders said they plan to build their own pharma company rather than join Big Pharma.
融资历史与报道
| 融资日期 | 轮次 | 金额 | 投资方 | 来源 |
|---|---|---|---|---|
| — | YC 2024 冬季 | — | Y Combinator | ycombinator.com |
档案汇总自公开报道和公司官网。商业模式部分是 MaxBC 对这些材料的解读，不是已确认的事实；未知之处留空，不作猜测。 更新于 2026-10-12.